

Liesbeth C De Wreede

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6065067/publications.pdf>

Version: 2024-02-01

100
papers

2,524
citations

201575

27
h-index

214721

47
g-index

102
all docs

102
docs citations

102
times ranked

4032
citing authors

#	ARTICLE	IF	CITATIONS
1	The mstate package for estimation and prediction in non- and semi-parametric multi-state and competing risks models. <i>Computer Methods and Programs in Biomedicine</i> , 2010, 99, 261-274.	2.6	261
2	mstate : An R Package for the Analysis of Competing Risks and Multi-State Models. <i>Journal of Statistical Software</i> , 2011, 38, .	1.8	248
3	Autologous and Allogeneic Stem-Cell Transplantation for Transformed Chronic Lymphocytic Leukemia (Richter's Syndrome): A Retrospective Analysis From the Chronic Lymphocytic Leukemia Subcommittee of the Chronic Leukemia Working Party and Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. <i>Journal of Clinical Oncology</i> , 2012, 30, 2211-2217.	0.8	110
4	Selective graft-versus-leukemia depends on magnitude and diversity of the alloreactive T cell response. <i>Journal of Clinical Investigation</i> , 2017, 127, 517-529.	3.9	107
5	Allogeneic stem cell transplantation for older advanced MDS patients: improved survival with young unrelated donor in comparison with HLA-identical siblings. <i>Leukemia</i> , 2013, 27, 604-609.	3.3	105
6	Sensitivity of hematological malignancies to graft-versus-host effects: an EBMT megafile analysis. <i>Leukemia</i> , 2014, 28, 2235-2240.	3.3	93
7	Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European Society of Blood and Marrow Transplantation. <i>Haematologica</i> , 2018, 103, 237-245.	1.7	82
8	Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. <i>British Journal of Haematology</i> , 2015, 171, 239-246.	1.2	80
9	Stem cell transplantation in severe congenital neutropenia: an analysis from the European Society for Blood and Marrow Transplantation. <i>Blood</i> , 2015, 126, 1885-1892.	0.6	76
10	Should the standard dimethyl sulfoxide concentration be reduced? Results of a European Group for Blood and Marrow Transplantation prospective noninterventonal study on usage and side effects of dimethyl sulfoxide. <i>Transfusion</i> , 2014, 54, 2514-2522.	0.8	75
11	MYD88 mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavorable prognosis. <i>Haematologica</i> , 2020, 105, 424-434.	1.7	55
12	Hematopoietic stem cell transplantation in T-prolymphocytic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation and the Royal Marsden Consortium. <i>Leukemia</i> , 2012, 26, 972-976.	3.3	53
13	Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2017, 52, 372-380.	1.3	53
14	Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndromes: a retrospective multicenter study of the European Society of Blood and Marrow Transplantation. <i>Haematologica</i> , 2015, 100, 400-408.	1.7	50
15	Allogeneic Stem Cell Transplantation for Patients Age \geq 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 44-52.	2.0	49
16	Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis. <i>Haematologica</i> , 2019, 104, 1782-1788.	1.7	48
17	Family Mismatched Allogeneic Stem Cell Transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 522-528.	2.0	48
18	Monosomal karyotype predicts poor survival after allogeneic stem cell transplantation in chromosome 7 abnormal myelodysplastic syndrome and secondary acute myeloid leukemia. <i>Leukemia</i> , 2013, 27, 879-888.	3.3	47

#	ARTICLE	IF	CITATIONS
19	Enhanced labile plasma iron and outcome in acute myeloid leukaemia and myelodysplastic syndrome after allogeneic haemopoietic cell transplantation (ALLIVE): a prospective, multicentre, observational trial. <i>Lancet Haematology</i> , 2018, 5, e201-e210.	2.2	44
20	Myeloablative T cell-depleted alloSCT with early sequential prophylactic donor lymphocyte infusion is an efficient and safe post-remission treatment for adult ALL. <i>Bone Marrow Transplantation</i> , 2014, 49, 287-291.	1.3	41
21	Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: A retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EBMT). <i>American Journal of Hematology</i> , 2021, 96, 69-79.	2.0	40
22	Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). <i>Bone Marrow Transplantation</i> , 2020, 55, 681-694.	1.3	39
23	Multi-state analysis illustrates treatment success after stem cell transplantation for acute myeloid leukemia followed by donor lymphocyte infusion. <i>Haematologica</i> , 2016, 101, 506-514.	1.7	38
24	Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. <i>British Journal of Haematology</i> , 2017, 177, 759-765.	1.2	38
25	External validation of models for KIR2DS1/KIR3DL1-informed selection of hematopoietic cell donors fails. <i>Blood</i> , 2020, 135, 1386-1395.	0.6	36
26	Risk factors for treatment failure after allogeneic transplantation of patients with CLL: a report from the European Society for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2017, 52, 552-560.	1.3	35
27	Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens. <i>Annals of Hematology</i> , 2018, 97, 255-266.	0.8	30
28	The burden of invasive infections in neutropenic patients: incidence, outcomes, and use of granulocyte transfusions. <i>Transfusion</i> , 2019, 59, 160-168.	0.8	29
29	Real-world outcomes of advanced melanoma patients not represented in phase III trials. <i>International Journal of Cancer</i> , 2020, 147, 3461-3470.	2.3	27
30	Centre characteristics and procedure-related factors have an impact on outcomes of allogeneic transplantation for patients with CLL: a retrospective analysis from the European Society for Blood and Marrow Transplantation (EBMT). <i>British Journal of Haematology</i> , 2017, 178, 521-533.	1.2	26
31	Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia. <i>Leukemia</i> , 2019, 33, 686-695.	3.3	24
32	Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation. <i>Haematologica</i> , 2019, 104, 929-936.	1.7	23
33	Comparison of Dynamic International Prognostic Scoring System and MYelofibrosis SECondary to PV and ET Prognostic Model for Prediction of Outcome in Polycythemia Vera and Essential Thrombocythemia Myelofibrosis after Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e204-e208.	2.0	23
34	Intentional donor lymphocyte-induced limited acute graft-versus-host disease is essential for long-term survival of relapsed acute myeloid leukemia after allogeneic stem cell transplantation. <i>Haematologica</i> , 2014, 99, 751-758.	1.7	21
35	Generation and infusion of multi-antigen-specific T cells to prevent complications early after T-cell depleted allogeneic stem cell transplantation—a phase I/II study. <i>Leukemia</i> , 2020, 34, 831-844.	3.3	21
36	Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation: a retrospective analysis of the EBMT chronic malignancies working party. <i>Bone Marrow Transplantation</i> , 2017, 52, 1519-1525.	1.3	19

#	ARTICLE	IF	CITATIONS
37	Prognostic pre-transplant factors in myelodysplastic syndromes primarily treated by high dose allogeneic hematopoietic stem cell transplantation: a retrospective study of the MDS subcommittee of the CMWP of the EBMT. <i>Annals of Hematology</i> , 2016, 95, 1971-1978.	0.8	18
38	Natural killer cell alloreactivity in HLA-haploidentical hematopoietic transplantation: a study on behalf of the CTIWP of the EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 1900-1907.	1.3	18
39	Impact of primary disease on outcome after allogeneic stem cell transplantation for transformed secondary acute leukaemia. <i>British Journal of Haematology</i> , 2019, 185, 725-732.	1.2	17
40	Real-world Outcomes of First-line Anti-PD-1 Therapy for Advanced Melanoma: A Nationwide Population-based Study. <i>Journal of Immunotherapy</i> , 2020, 43, 256-264.	1.2	17
41	Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma: results from the EBMT NMAM2000 prospective trial. <i>Bone Marrow Transplantation</i> , 2015, 50, 505-510.	1.3	16
42	A prospective non-interventional study on the impact of transfusion burden and related iron toxicity on outcome in myelodysplastic syndromes undergoing allogeneic hematopoietic cell transplantation. <i>Leukemia and Lymphoma</i> , 2019, 60, 2404-2414.	0.6	15
43	Survival outcomes of patients with advanced mucosal melanoma diagnosed from 2013 to 2017 in the Netherlands â€” A nationwide population-based study. <i>European Journal of Cancer</i> , 2020, 137, 127-135.	1.3	14
44	Effectivity of a strategy in elderly AML patients to reach allogeneic stem cell transplantation using intensive chemotherapy: Long-term survival is dependent on complete remission after first induction therapy. <i>Leukemia Research</i> , 2016, 46, 45-50.	0.4	13
45	Role of allogeneic transplantation in chronic myelomonocytic leukemia: an international collaborative analysis. <i>Blood</i> , 2022, 140, 1408-1418.	0.6	13
46	Baseline Characteristics Predicting Very Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Patients With High Cytogenetic Risk Chronic Lymphocytic Leukemiaâ€” A Retrospective Analysis From the Chronic Malignancies Working Party of the EBMT. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 667-675.e2.	0.2	12
47	Discontinuation of anti-PD-1 monotherapy in advanced melanomaâ€”Outcomes of daily clinical practice. <i>International Journal of Cancer</i> , 2022, 150, 317-326.	2.3	12
48	Improved relapse-free survival after autologous stem cell transplantation does not translate into better quality of life in chronic lymphocytic leukemia: Lessons from the randomized European Society for Blood and Marrow Transplantationâ€”Intergroup study. <i>American Journal of Hematology</i> , 2014, 89, 174-180.	2.0	10
49	Construction and assessment of prediction rules for binary outcome in the presence of missing predictor data using multiple imputation and cross-validation: Methodological approach and data-based evaluation. <i>Biometrical Journal</i> , 2020, 62, 724-741.	0.6	10
50	Treosulfan conditioning for allogeneic transplantation in multiple myeloma â€” improved overall survival in first line haematopoietic stem cell transplantation â€” a large retrospective study by the Chronic Malignancies Working Party of the EBMT. <i>British Journal of Haematology</i> , 2020, 189, e213-e217.	1.2	10
51	Allogeneic stem cell transplantation for acquired pure red cell aplasia. <i>American Journal of Hematology</i> , 2019, 94, E294-E296.	2.0	9
52	Integrating biological HLA-DPB1 mismatch models to predict survival after unrelated hematopoietic cell transplantation. <i>Haematologica</i> , 2023, 108, 645-652.	1.7	9
53	Donor lymphocyte infusions for the treatment of chronic myeloid leukemia relapse following peripheral blood or bone marrow stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2013, 48, 837-842.	1.3	8
54	Beneficial role of CD8+ T-cell reconstitution after HLA-haploidentical stem cell transplantation for high-risk acute leukaemias: results from a clinico-biological EBMT registry study mostly in the T-cell-depleted setting. <i>Bone Marrow Transplantation</i> , 2019, 54, 867-876.	1.3	8

#	ARTICLE	IF	CITATIONS
55	Thiotepa+busulfan+fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 1593-1602.	1.3	8
56	Selection patterns of B-cell receptors and the natural history of follicular lymphoma. <i>British Journal of Haematology</i> , 2016, 175, 972-975.	1.2	7
57	Reduced intensity conditioning regimens including alkylating chemotherapy do not alter survival outcomes after allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia compared to low-intensity non-myeloablative conditioning. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2823-2834.	1.2	7
58	Upfront stem cell transplantation for newly diagnosed multiple myeloma with del(17p) and t(4;14): a study from the CMWP-EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 210-217.	1.3	7
59	Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party. <i>Bone Marrow Transplantation</i> , 2021, 56, 605-613.	1.3	6
60	Long-term risk of cancer development in adult patients with idiopathic aplastic anemia after treatment with anti-thymocyte globulin. <i>Haematologica</i> , 2017, 102, e382-e383.	1.7	5
61	Allogeneic Hematopoietic Stem Cell Transplantation in Hemophagocytic Lymphohistiocytosis (HLH) in Adults: A Retrospective Study of the Chronic Malignancies and Inborn Errors Working Parties (CMWP) of the EBMT. <i>Over</i>		
62	Benchmarking survival outcomes: A funnel plot for survival data. <i>Statistical Methods in Medical Research</i> , 2022, 31, 1171-1183.	0.7	5
63	Autologous hematopoietic cell transplantation for relapsed multiple myeloma performed with cells procured after previous transplantation—study on behalf of CMWP of the EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 633-640.	1.3	4
64	Integrating relative survival in multi-state models—a non-parametric approach. <i>Statistical Methods in Medical Research</i> , 2022, 31, 997-1012.	0.7	4
65	A dialogue on the use of arithmetic in geometry: Van Ceulen's and Snellius's <i>Fundamenta Arithmetica et Geometrica</i> . <i>Historia Mathematica</i> , 2010, 37, 376-402.	0.2	3
66	Donor T-cell responses and disease progression patterns of multiple myeloma. <i>Bone Marrow Transplantation</i> , 2017, 52, 1609-1615.	1.3	3
67	Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: Results of a prospective observational study. <i>Bone Marrow Transplantation</i> , 2021, 56, 692-695.	1.3	3
68	Timing for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Chronic Myelomonocytic Leukemia (CMML): A Joint Study from the International MDS/MPN Working Group and the Chronic Malignancies Working Party of the EBMT. <i>Blood</i> , 2019, 134, 4581-4581.	0.6	3
69	Impact of Graft-Versus-Host Disease On Relapse After Allogeneic Hematopoietic Stem Cell Transplantation, an EBMT Megafile Study. <i>Blood</i> , 2012, 120, 469-469.	0.6	3
70	The added value of multi-state modelling in a randomized controlled trial: The HOVON 102 study re-analyzed. <i>Cancer Medicine</i> , 2022, 11, 630-640.	1.3	3
71	Multiple imputation for cause-specific Cox models: Assessing methods for estimation and prediction. <i>Statistical Methods in Medical Research</i> , 2022, 31, 1860-1880.	0.7	3
72	Short-term efficacy and safety of antithymocyte globulin treatment in elderly patients with acquired aplastic anaemia. <i>British Journal of Haematology</i> , 2018, 180, 459-462.	1.2	2

#	ARTICLE	IF	CITATIONS
73	Nationwide Outcomes of Advanced Melanoma According to BRAFV600 Status. American Journal of Clinical Oncology: Cancer Clinical Trials, 2021, 44, 82-89.	0.6	2
74	Outcomes Of Haematopoietic Stem Cell Transplantation (HSCT) for Severe Congenital Neutropenia (SCN): Preliminary Results. Blood, 2013, 122, 3355-3355.	0.6	2
75	Mother Donors Improve Outcomes after HLA Haploidentical Transplantation: A Study by the Cellular Therapy and Immunobiology Working Party of the European Society for Blood and Marrow Transplantation. Transplantation and Cellular Therapy, 2022, 28, 206.e1-206.e6.	0.6	2
76	Personalized Decision Making on Genomic Testing in Early Breast Cancer: Expanding the MINDACT Trial with Decision-Analytic Modeling. Medical Decision Making, 2021, 41, 354-365.	1.2	1
77	Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party. Bone Marrow Transplantation, 2021, 56, 2367-2381.	1.3	1
78	Impact of early candidemia on the long-term outcome of allogeneic hematopoietic stem cell transplant in non-leukemic patients: an outcome analysis on behalf of IDWP of EBMT. Bone Marrow Transplantation, 2021, 56, 1563-1572.	1.3	1
79	Outcomes Following Second Allogeneic Haematopoietic Cell Transplantation in Patients with Myelofibrosis: A Retrospective Study on Behalf of the Chronic Malignancies Working Party of EBMT. Blood, 2019, 134, 698-698.	0.6	1
80	Allogeneic Hematopoietic Transplantation in Patients with CLL: Results of a Large Disease-Specific Risk Factor Analysis. Blood, 2015, 126, 3209-3209.	0.6	1
81	Hospital Variation in Cancer Treatments and Survival Outcomes of Advanced Melanoma Patients: Nationwide Quality Assurance in The Netherlands. Cancers, 2021, 13, 5077.	1.7	1
82	Family Mismatched Donor Transplantation for Myelofibrosis: A Retrospective Analysis of the EBMT Chronic Leukaemia Working Party. Blood, 2016, 128, 4655-4655.	0.6	1
83	Statistical Methods in HSCT and Cellular Therapies. , 2019, , 41-46.		1
84	Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Patients with Therapy-Related Myeloid Neoplasm: A Study from the Chronic Malignancies Working Party of the EBMT. Blood, 2019, 134, 45-45.	0.6	1
85	Real-world outcomes of advanced melanoma patients not represented in phase III trials.. Journal of Clinical Oncology, 2020, 38, 10042-10042.	0.8	1
86	Trends in Allogeneic Stem Cell Transplantation for Myelofibrosis in Europe between 1995-2018: An EBMT Retrospective Analysis. Blood, 2020, 136, 38-39.	0.6	1
87	Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT. Bone Marrow Transplantation, 2022, , .	1.3	1
88	Analysis of survival outcomes in haematopoietic cell transplant studies: Pitfalls and solutions. Bone Marrow Transplantation, 2022, 57, 1428-1434.	1.3	1
89	Treosulfan Conditioning for Allogeneic Transplantation in Multiple Myeloma â€œ Improved Overall Survival in first line Hematopoietic Stem Cell Transplantation. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e206.	0.2	0
90	Hospital variation in cancer treatments and survival outcomes of advanced melanoma patients: Nationwide quality assurance in the Netherlands.. Journal of Clinical Oncology, 2021, 39, e18641-e18641.	0.8	0

#	ARTICLE	IF	CITATIONS
91	Prognostic Pre-Transplant Factors in Myelodysplastic Syndromes Primarily Treated by Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Study on Behalf of the MDS Subcommittee of the Chronic Leukaemia Working Party of the EBMT. <i>Blood</i> , 2011, 118, 3014-3014.	0.6	0
92	Identification of Baseline Characteristics That Predict Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Chronic Lymphocytic Leukemia Patients - a Retrospective Analysis from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.. <i>Blood</i> , 2016, 128, 522-522.	0.6	0
93	Center Characteristics and Procedure-Related Factors Have an Impact on Outcomes of Allogeneic Transplantation for Patients with CLL: A Retrospective Analysis from the European Society for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2016, 128, 4663-4663.	0.6	0
94	Treosulfan Conditioning for Allogeneic Transplantation in Multiple Myeloma Improved Overall Survival in Upfront Hematopoietic Stem Cell Transplantation – a Large Retrospective Study By the Chronic Malignancies Working Party of the EBMT. <i>Blood</i> , 2018, 132, 3464-3464.	0.6	0
95	Classification of Donor KIR-Genotype Information to Predict Outcome after Unrelated Hematopoietic Stem Cell Transplantation: The Jury Is Still out. <i>Blood</i> , 2018, 132, 2162-2162.	0.6	0
96	Patient Bone Marrow Chimerism at Time of Donor Lymphocyte Infusion Predicts Development of Graft Versus Host Disease. <i>Blood</i> , 2018, 132, 2132-2132.	0.6	0
97	Autologous and Allogeneic Hematopoietic Stem-Cell Transplantation for Patients with Richter's Syndrome: A Large Series from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. <i>Blood</i> , 2019, 134, 2053-2053.	0.6	0
98	Association of Donor-Recipient HLA Matching with Outcome of Unrelated Donor Hematopoietic Stem Cell Transplantation: A Study from the Cellular Therapy and Immunobiology Working Party (CTIWP) of the European Society for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2019, 134, 3281-3281.	0.6	0
99	Daratumumab after Allogeneic Hematopoietic Stem Cell Transplantation in Multiple Myeloma: Safety and Efficacy. a Retrospective Study from the Cmwp EBMT. <i>Blood</i> , 2020, 136, 26-27.	0.6	0
100	Does a Change in IPSS-R between Diagnosis and Transplant Have an Impact on Transplant Outcome in Patients with MDS? a Retrospective Analysis from the EBMT Chronic Malignancies Working Party. <i>Blood</i> , 2020, 136, 39-40.	0.6	0